局部晚期鼻咽癌紫杉醇同步放化疗的临床疗效观察  

Concurrent radiotherapy and chemotherapy with paclitaxel in treatment of locally advanced nasopharyngeal carcinoma

作　　者：王耀辉[1] 贾海艳[1] 曲卓慧[1] 

机构地区：[1]四平市中心医院放疗科,136000

出　　处：《中国实用医药》2010年第6期15-16,共2页China Practical Medicine

摘　　要：目的评价紫杉醇同步放化疗治疗局部晚期鼻咽癌的疗效及毒副反应。方法62例局部晚期鼻咽癌患者随机分为同步放化疗组31例和单纯放疗组31例。同步放化疗组每周同步应用紫杉醇60mg。两组患者均采用常规放疗,鼻咽部剂量为68～74Gy/7周。结果化放组CR率为83.9%,而单放组为67.7%(P<0.05)。毒副反应主要表现为Ⅰ度白细胞减少及Ⅲ度口腔黏膜反应。结论紫杉醇同步放化疗能提高晚期鼻咽癌患者的有效率,而且毒副作用可以耐受。Objective To evaluate the efficacy and toxicity of concurrent chemoradiotherapy with paclitaxel on locally advanced nasopharyngeal cancer. Methods 62 cases of locally advanced nasopharyngeal carcinoma patients were randomly divided into two groups,31 patients with concurrent chemoradiotherapy and 31 patients with radiotherapy alone. Concurrent chemoradiotherapy with weekly paclitaxel simultaneous application of 60 mg. Two groups of patients used conventional radiotherapy nasopharyngeal dose 68-74 Gy/7 weeks. Results CR rate of concurrent chemoradiotherapy group was 83. 9% ,while the radiotherapy alone group was 67. 7% （P〈0. 05）. The major toxic reactions manifested as leukopenia gradeⅠand Ⅲ degree of reaction of oral mucosa. Conclusion Concurrent chemoradiotherapy with paclitaxel can improve the efficiency of patients with advanced nasopharyngeal carcinoma,and the side effects can be tolerated.

关 键 词：鼻咽肿瘤 化学疗法 放射疗法 紫杉醇 

分 类 号：R739.63[医药卫生—肿瘤]